Cited 7 times in
Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for Intravenous Immunoglobulin-Resistant Kawasaki Disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김동수 | - |
dc.date.accessioned | 2018-08-28T16:44:26Z | - |
dc.date.available | 2018-08-28T16:44:26Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/161891 | - |
dc.description.abstract | PURPOSE: Intravenous immunoglobulin (IVIG) is the standard treatment for Kawasaki disease (KD). However, there is still no standard treatment for IVIG-resistant KD. This study aimed to evaluate the efficacy of low-dose methotrexate (MTX) as a treatment for IVIG-resistant KD. MATERIALS AND METHODS: We retrospectively analyzed 10-year data for patients with IVIG-resistant KD who were administered MTX at Severance Children's Hospital. RESULTS: The subjects included 75 patients with KD aged 5 months to 9.2 years who had been administered MTX. Their maximum body temperatures decreased significantly within 24 h of therapy. The patients' C-reactive protein levels were significantly lower 1 week after administering the first dose of MTX than those before treatment. No adverse effect for MTX was observed. CONCLUSION: MTX treatment of IVIG-resistant KD resulted in rapid defervescence, improvement of clinical symptoms, and normalization of acute-phase reactants in all patients. Thus, MTX could be a candidate treatment for IVIG-resistant KD. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | C-Reactive Protein/analysis | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Preschool Child | - |
dc.subject.MESH | Coronary Vessels/pathology | - |
dc.subject.MESH | Demography | - |
dc.subject.MESH | Drug Dose-Response Relationship | - |
dc.subject.MESH | Combination Drug Therapy | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Intravenous/*therapeutic use Immunoglobulins | - |
dc.subject.MESH | Infant | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Methotrexate/administration & dosage/*therapeutic use | - |
dc.subject.MESH | Mucocutaneous Lymph Node Syndrome/blood/*drug therapy | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Steroids/therapeutic use | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for Intravenous Immunoglobulin-Resistant Kawasaki Disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Pediatrics | - |
dc.contributor.googleauthor | Hyejin Jang | - |
dc.contributor.googleauthor | Kyu Yeun Kim | - |
dc.contributor.googleauthor | Dong Soo Kim | - |
dc.identifier.doi | 10.3349/ymj.2018.59.1.113 | - |
dc.contributor.localId | A00405 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 29214785 | - |
dc.subject.keyword | Kawasaki disease | - |
dc.subject.keyword | coronary artery lesion | - |
dc.subject.keyword | immunoglobulin-resistant Kawasaki disease | - |
dc.subject.keyword | methotrexate | - |
dc.contributor.alternativeName | Kim, Dong Soo | - |
dc.contributor.affiliatedAuthor | Kim, Dong Soo | - |
dc.citation.volume | 59 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 113 | - |
dc.citation.endPage | 118 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.59(1) : 113-118, 2018 | - |
dc.identifier.rimsid | 59482 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.